The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
January 30th 2025
Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.
REMS Review: Barriers to Actionable Data Collection
September 25th 2013Manufacturers often select their specialty drug distribution strategy based on the level of REMS reporting required by the FDA. What are some things keeping specialty pharmacies and manufacturers from collecting the data they truly want?
Read More
SPAARx Advocacy Prompts Positive Response from HHS on HI-TECH Act Rules
September 24th 2013In response to the lobbying efforts of SPAARx and other industry organizations over the past months, the Department of Health and Human Services (HHS) provided revised guidance on remuneration for refill reminders and other similar communications.
Read More
Are Patients Taking Oral Cancer Regimens as Prescribed?
September 23rd 2013Between 21% and 28% of patients taking an oral therapy for hepatocellular carcinoma (HCC) were nonadherent to treatment. Certain groups of patients may benefit from counseling services that promote improved adherence.
Read More
UHC to Launch New Specialty Pharmacy Program
September 11th 2013UHC, an alliance of the nation's leading nonprofit academic medical centers, is unveiling a new specialty pharmacy program in late 2013/early 2014 to provide patients with access to the specialty medications they need at the hospitals where they are treated.
Read More
URAC Launches New Accreditation Programs for Clinical Integration and Accountable Care
September 5th 2013URAC, an independent accreditation organization advancing quality and value throughout health care, announced the launch of 2 new accreditation programs for Clinical Integration and Accountable Care to address the changing healthcare landscape.
Read More
Reports from the United States and Europe reference the lack of long-term effectiveness studies and the lack of comparative effectiveness studies as challenges in determining the most appropriate initial biologic disease-modifying antirheumatic drug (DMARD) treatment for patients with rheumatoid arthritis.
Read More
An All-Oral Regimen for Hepatitis C Succeeds in 68% of Difficult-to-Treat Patients
August 29th 2013Sixty-eight percent of patients with preexisting liver damage and other poor prognostic factors treated with a combination of sofosbuvir and ribavirin attained functional cure of hepatitis C, as measured by sustained viral response 24 weeks after the end of treatment.
Read More